Cargando…
Evaluation of the HPA Axis’ Response to Pharmacological Challenges in Experimental and Clinical Early-Life Stress-Associated Depression
Early-life stress (ELS) is associated with a higher risk of psychopathologies in adulthood, such as depression, which may be related to persistent changes in the hypothalamic-pituitary-adrenal (HPA) axis. This study aimed to evaluate the effects of ELS on the functioning of the HPA axis in clinical...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society for Neuroscience
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814478/ https://www.ncbi.nlm.nih.gov/pubmed/33318074 http://dx.doi.org/10.1523/ENEURO.0222-20.2020 |
_version_ | 1783638062484422656 |
---|---|
author | Barroca, Nayara Cobra Barreiro Baes, Cristiane Von Werne Martins-Monteverde, Camila Maria Severi Bosaipo, Nayanne Beckmann Santos da Silva Umeoka, Marcia Tejada, Julian Antunes-Rodrigues, José de Castro, Margaret Juruena, Mario Francisco Garcia-Cairasco, Norberto Umeoka, Eduardo Henrique de Lima |
author_facet | Barroca, Nayara Cobra Barreiro Baes, Cristiane Von Werne Martins-Monteverde, Camila Maria Severi Bosaipo, Nayanne Beckmann Santos da Silva Umeoka, Marcia Tejada, Julian Antunes-Rodrigues, José de Castro, Margaret Juruena, Mario Francisco Garcia-Cairasco, Norberto Umeoka, Eduardo Henrique de Lima |
author_sort | Barroca, Nayara Cobra Barreiro |
collection | PubMed |
description | Early-life stress (ELS) is associated with a higher risk of psychopathologies in adulthood, such as depression, which may be related to persistent changes in the hypothalamic-pituitary-adrenal (HPA) axis. This study aimed to evaluate the effects of ELS on the functioning of the HPA axis in clinical and experimental situations. Clinically, patients with current depressive episodes, with and without ELS, and healthy controls, composed the sample. Subjects took a capsule containing placebo, fludrocortisone, prednisolone, dexamethasone or spironolactone followed by an assessment of plasma cortisol the morning after. Experimentally, male Wistar rats were submitted to ELS protocol based on variable, unpredictable stressors from postnatal day (PND)1 to PND21. On PND65 animals were behaviorally evaluated through the forced-swimming test (FST). At PND68, pharmacological challenges started, using mifepristone, dexamethasone, spironolactone, or fludrocortisone, and corticosterone levels were determined 3 h after injections. Cortisol response of the patients did not differ significantly from healthy subjects, regardless of their ELS history, and it was lower after fludrocortisone, prednisolone, and dexamethasone compared with placebo, indicating the suppression of plasma cortisol by all these treatments. Animals exposed to ELS presented altered phenotype as indicated by an increased immobility time in the FST when compared with control, but no significant long-lasting effects of ELS were observed on the HPA axis response. Limitations on the way the volunteers were sampled may have contributed to the lack of ELS effects on the HPA axis, pointing out the need for further research to understand these complex phenomena |
format | Online Article Text |
id | pubmed-7814478 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Society for Neuroscience |
record_format | MEDLINE/PubMed |
spelling | pubmed-78144782021-01-21 Evaluation of the HPA Axis’ Response to Pharmacological Challenges in Experimental and Clinical Early-Life Stress-Associated Depression Barroca, Nayara Cobra Barreiro Baes, Cristiane Von Werne Martins-Monteverde, Camila Maria Severi Bosaipo, Nayanne Beckmann Santos da Silva Umeoka, Marcia Tejada, Julian Antunes-Rodrigues, José de Castro, Margaret Juruena, Mario Francisco Garcia-Cairasco, Norberto Umeoka, Eduardo Henrique de Lima eNeuro Research Article: Negative Results Early-life stress (ELS) is associated with a higher risk of psychopathologies in adulthood, such as depression, which may be related to persistent changes in the hypothalamic-pituitary-adrenal (HPA) axis. This study aimed to evaluate the effects of ELS on the functioning of the HPA axis in clinical and experimental situations. Clinically, patients with current depressive episodes, with and without ELS, and healthy controls, composed the sample. Subjects took a capsule containing placebo, fludrocortisone, prednisolone, dexamethasone or spironolactone followed by an assessment of plasma cortisol the morning after. Experimentally, male Wistar rats were submitted to ELS protocol based on variable, unpredictable stressors from postnatal day (PND)1 to PND21. On PND65 animals were behaviorally evaluated through the forced-swimming test (FST). At PND68, pharmacological challenges started, using mifepristone, dexamethasone, spironolactone, or fludrocortisone, and corticosterone levels were determined 3 h after injections. Cortisol response of the patients did not differ significantly from healthy subjects, regardless of their ELS history, and it was lower after fludrocortisone, prednisolone, and dexamethasone compared with placebo, indicating the suppression of plasma cortisol by all these treatments. Animals exposed to ELS presented altered phenotype as indicated by an increased immobility time in the FST when compared with control, but no significant long-lasting effects of ELS were observed on the HPA axis response. Limitations on the way the volunteers were sampled may have contributed to the lack of ELS effects on the HPA axis, pointing out the need for further research to understand these complex phenomena Society for Neuroscience 2021-01-13 /pmc/articles/PMC7814478/ /pubmed/33318074 http://dx.doi.org/10.1523/ENEURO.0222-20.2020 Text en Copyright © 2021 Barroca et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. |
spellingShingle | Research Article: Negative Results Barroca, Nayara Cobra Barreiro Baes, Cristiane Von Werne Martins-Monteverde, Camila Maria Severi Bosaipo, Nayanne Beckmann Santos da Silva Umeoka, Marcia Tejada, Julian Antunes-Rodrigues, José de Castro, Margaret Juruena, Mario Francisco Garcia-Cairasco, Norberto Umeoka, Eduardo Henrique de Lima Evaluation of the HPA Axis’ Response to Pharmacological Challenges in Experimental and Clinical Early-Life Stress-Associated Depression |
title | Evaluation of the HPA Axis’ Response to Pharmacological Challenges in Experimental and Clinical Early-Life Stress-Associated Depression |
title_full | Evaluation of the HPA Axis’ Response to Pharmacological Challenges in Experimental and Clinical Early-Life Stress-Associated Depression |
title_fullStr | Evaluation of the HPA Axis’ Response to Pharmacological Challenges in Experimental and Clinical Early-Life Stress-Associated Depression |
title_full_unstemmed | Evaluation of the HPA Axis’ Response to Pharmacological Challenges in Experimental and Clinical Early-Life Stress-Associated Depression |
title_short | Evaluation of the HPA Axis’ Response to Pharmacological Challenges in Experimental and Clinical Early-Life Stress-Associated Depression |
title_sort | evaluation of the hpa axis’ response to pharmacological challenges in experimental and clinical early-life stress-associated depression |
topic | Research Article: Negative Results |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814478/ https://www.ncbi.nlm.nih.gov/pubmed/33318074 http://dx.doi.org/10.1523/ENEURO.0222-20.2020 |
work_keys_str_mv | AT barrocanayaracobrabarreiro evaluationofthehpaaxisresponsetopharmacologicalchallengesinexperimentalandclinicalearlylifestressassociateddepression AT baescristianevonwerne evaluationofthehpaaxisresponsetopharmacologicalchallengesinexperimentalandclinicalearlylifestressassociateddepression AT martinsmonteverdecamilamariaseveri evaluationofthehpaaxisresponsetopharmacologicalchallengesinexperimentalandclinicalearlylifestressassociateddepression AT bosaiponayannebeckmann evaluationofthehpaaxisresponsetopharmacologicalchallengesinexperimentalandclinicalearlylifestressassociateddepression AT santosdasilvaumeokamarcia evaluationofthehpaaxisresponsetopharmacologicalchallengesinexperimentalandclinicalearlylifestressassociateddepression AT tejadajulian evaluationofthehpaaxisresponsetopharmacologicalchallengesinexperimentalandclinicalearlylifestressassociateddepression AT antunesrodriguesjose evaluationofthehpaaxisresponsetopharmacologicalchallengesinexperimentalandclinicalearlylifestressassociateddepression AT decastromargaret evaluationofthehpaaxisresponsetopharmacologicalchallengesinexperimentalandclinicalearlylifestressassociateddepression AT juruenamariofrancisco evaluationofthehpaaxisresponsetopharmacologicalchallengesinexperimentalandclinicalearlylifestressassociateddepression AT garciacairasconorberto evaluationofthehpaaxisresponsetopharmacologicalchallengesinexperimentalandclinicalearlylifestressassociateddepression AT umeokaeduardohenriquedelima evaluationofthehpaaxisresponsetopharmacologicalchallengesinexperimentalandclinicalearlylifestressassociateddepression |